Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Blood Portfolio issue just before ASH25.
Takeaway: ASXL1-mt associated with inf outcome/acquisition of resistant mutations in CML. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.”
Title: Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
Authors: Naranie Shanmuganathan, David T. Yeung, Carol Wadham, Adelina Fernandes, Muneeza Maqsood, NurHezrin Shahrin, Verity Saunders, Rosalie R. Kenyon, Ming Lin, John Toubia, Joe McConnell, Dominic Kaczorowski, David M. Ross, Agnes S. M. Yong, Lynette Chee, Jake Shortt, Nicholas Viiala, Jodi Braley, Chung Hoow Kok, Timothy P. Hughes, Susan Branford
More posts featuring Talha Badar on OncoDaily.